Form 4: Allogene Director Arie Belldegrun Boosts Stake with New Equity Awards

Allogene Therapeutics Director Arie Belldegrun reported significant new equity awards, including stock options and restricted stock units, alongside existing indirect and direct common stock holdings.

Summary

• Director Arie Belldegrun of Allogene Therapeutics, Inc. reported changes in beneficial ownership.
• Received a stock option to purchase 929,913 shares of common stock at an exercise price of $1.87 per share, vesting 25% on February 2, 2027, and the remainder in 36 equal monthly installments thereafter.
• Received an award of 263,033 Restricted Stock Units (RSUs), which will vest in 4 successive equal annual installments over four years from February 2, 2026, subject to continued service.
• Holds a direct beneficial ownership of 2,236,816 shares of Common Stock.
• Holds indirect beneficial ownership of 4,710,120 shares through Bellco Legacy Trust fbo Rebecka Belldegrun, where the reporting person's spouse is trustee and beneficiary.
• Holds indirect beneficial ownership of 1,798,163 shares through Vida Ventures LLC, where the reporting person is a Senior Managing Director of the managing entity, disclaiming beneficial ownership except for pecuniary interest.
• Holds indirect beneficial ownership of 1,724,137 shares through Vida Ventures III, L.P. and Vida Ventures III-A, L.P., where the reporting person is a Senior Managing Director of the managing entity, disclaiming beneficial ownership except for pecuniary interest.
• Holds indirect beneficial ownership of 539,867 shares through Bellco Legacy LLC, which is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the director's increased equity stake, through both direct holdings and new awards, suggests continued alignment with shareholder interests and confidence in Allogene's long-term prospects.

Positives

• A director receiving new equity awards (stock options and RSUs) can signal confidence in the company's future prospects and aligns their interests with shareholders.
• The exercise price of the stock option ($1.87) provides a clear benchmark for future performance, incentivizing the director to drive share price appreciation.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity awards to directors are a common practice in the biotechnology sector, aligning management incentives with shareholder interests, particularly in companies like Allogene Therapeutics that are often in development stages. This type of compensation structure is designed to motivate long-term value creation.

Related Party Transactions

• Indirect ownership through Bellco Legacy Trust fbo Rebecka Belldegrun, where the reporting person's spouse is trustee and beneficiary.
• Indirect ownership through Bellco Legacy LLC, which is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.
• Indirect ownership through Vida Ventures LLC, Vida Ventures III, L.P., and Vida Ventures III-A, L.P., where the reporting person is a Senior Managing Director of the managing entities, disclaiming beneficial ownership except for pecuniary interest.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to significant equity holdings and new awards, potentially fostering greater confidence in long-term value creation.

Next Steps

• Vesting of 25% of stock options on February 2, 2027, with remaining shares vesting in 36 equal monthly installments thereafter.
• Vesting of Restricted Stock Units in 4 successive equal annual installments over four years from February 2, 2026, subject to continued service.

Key Dates

Recommendation

The filing indicates a director's continued commitment to Allogene Therapeutics through significant equity awards and existing holdings. While this is a positive signal of insider confidence, it is a routine compensation event and does not present new fundamental information to warrant a 'buy' or 'sell' recommendation based solely on this Form 4. Investors should 'hold' and monitor future operational and financial developments.

Keywords

Allogene Therapeutics, ALLO, Arie Belldegrun, Form 4, Insider Transaction, Stock Option, Restricted Stock Units, Equity Awards, Director Ownership, Beneficial Ownership, Biotechnology